HealthDay News — In a study published online July 9 in Blood Cancer Discovery, real-world outcomes are described for teclistamab, a T-cell-engaging bispecific antibody that targets multiple myeloma ...

Researchers sought to improve HBOC genetic testing in underserved areas through cancer risk assessment at mammography.

The tissue damage, anatomical distortion, and lack of surgical landmarks caused by the primary treatment present major challenges to surgeons performing salvage RARP.

Results from the POLARGO trial “reinforce the benefit of adding polatuzumab to chemoimmunotherapy,” said Matthew Matasar, MD.

US researchers analyzed national death certificate data to compare trends in hepatocellular carcinoma (HCC)-related mortality and underlying etiologies of chronic liver disease linked to HCC-related ...

Results of a meta-analysis suggest that ctDNA positivity is a “biomarker for poor postoperative recurrence and survival outcomes in NSCLC patients,” researchers wrote.